DK2662390T3 - Interferon alpha receptor 1-antistoffer og anvendelse heraf - Google Patents

Interferon alpha receptor 1-antistoffer og anvendelse heraf

Info

Publication number
DK2662390T3
DK2662390T3 DK13162333.2T DK13162333T DK2662390T3 DK 2662390 T3 DK2662390 T3 DK 2662390T3 DK 13162333 T DK13162333 T DK 13162333T DK 2662390 T3 DK2662390 T3 DK 2662390T3
Authority
DK
Denmark
Prior art keywords
antibodies
interferon alpha
alpha receptor
receptor
interferon
Prior art date
Application number
DK13162333.2T
Other languages
Danish (da)
English (en)
Inventor
Josephine M Cardarelli
Alison Witte
Mohan Srinivasan
Original Assignee
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc filed Critical Squibb & Sons Llc
Application granted granted Critical
Publication of DK2662390T3 publication Critical patent/DK2662390T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK13162333.2T 2004-06-21 2005-06-20 Interferon alpha receptor 1-antistoffer og anvendelse heraf DK2662390T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58174704P 2004-06-21 2004-06-21
EP05787743.3A EP1781705B1 (en) 2004-06-21 2005-06-20 Interferon alpha receptor i antibodies and their uses

Publications (1)

Publication Number Publication Date
DK2662390T3 true DK2662390T3 (da) 2017-11-06

Family

ID=35782299

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13162333.2T DK2662390T3 (da) 2004-06-21 2005-06-20 Interferon alpha receptor 1-antistoffer og anvendelse heraf
DK05787743.3T DK1781705T3 (en) 2004-06-21 2005-06-20 Interferon-alpha receptor 1 antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05787743.3T DK1781705T3 (en) 2004-06-21 2005-06-20 Interferon-alpha receptor 1 antibodies and uses thereof

Country Status (18)

Country Link
US (6) US7662381B2 (enExample)
EP (2) EP2662390B1 (enExample)
JP (3) JP5160887B2 (enExample)
KR (4) KR101541658B1 (enExample)
CN (3) CN102603894B (enExample)
AU (1) AU2005258077C1 (enExample)
CA (1) CA2570823C (enExample)
CY (2) CY1115875T1 (enExample)
DK (2) DK2662390T3 (enExample)
ES (2) ES2643237T3 (enExample)
HU (1) HUE035082T2 (enExample)
LT (1) LT2662390T (enExample)
MX (1) MX2007000023A (enExample)
PL (2) PL1781705T3 (enExample)
PT (2) PT1781705E (enExample)
RU (2) RU2412202C2 (enExample)
SI (2) SI2662390T1 (enExample)
WO (1) WO2006002177A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011409A (es) * 2003-04-23 2005-12-12 Medarex Inc Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal.
PT1781705E (pt) 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
WO2006054748A1 (ja) * 2004-11-22 2006-05-26 Ginkgo Biomedical Research Institute Co., Ltd. 腎炎の治療剤
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
NZ585064A (en) * 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
EP3009449B1 (en) 2008-07-16 2018-06-06 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
CN101580546B (zh) * 2009-06-04 2011-09-14 中国疾病预防控制中心病毒病预防控制所 人源抗人干扰素α抗体及其应用
HUE032917T2 (hu) 2009-09-03 2017-11-28 Medimmune Llc 1-es típusú interferon diagnosztikum
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
WO2014134223A1 (en) * 2013-02-26 2014-09-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9902770B2 (en) * 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20160251441A1 (en) * 2013-10-25 2016-09-01 Medimmune, Llc Antibody purification
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
WO2016176222A1 (en) 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
FI3769781T3 (fi) 2015-08-19 2023-06-07 Astrazeneca Ab Stabiili anti-ifnar1-formulaatio
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CN108409862B (zh) * 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US20200031943A1 (en) 2017-03-21 2020-01-30 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
EA202092088A1 (ru) * 2018-03-05 2020-11-13 Янссен Фармацевтика Нв Антитела анти-phf-тау и их применение
CN112135623B (zh) * 2018-06-01 2024-03-26 Ilc医疗有限公司 与疾病的治疗有关的组合物和方法
CN112041339B (zh) * 2018-09-18 2024-04-26 天境生物科技(杭州)有限公司 用于治疗自身免疫病的抗ifnar1抗体
CN113728006B (zh) * 2019-01-31 2022-10-14 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
WO2020165437A1 (en) 2019-02-15 2020-08-20 Astrazeneca Ab Type i interferon-mediated disorders
EP4058060B1 (en) 2019-11-11 2025-02-19 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
WO2021214382A1 (en) * 2020-04-20 2021-10-28 Faron Pharmaceuticals Oy Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
EP4566667A3 (en) 2020-05-29 2025-09-03 AstraZeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
AU2021383537A1 (en) 2020-11-18 2023-06-29 Astrazeneca Ab Steroid sparing
EP4326322A1 (en) * 2021-04-23 2024-02-28 Astrazeneca AB Treatment of cutaneous lupus erythematous
PL4192882T3 (pl) 2021-04-23 2025-04-28 Astrazeneca Ab Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem
KR20250092298A (ko) 2021-04-23 2025-06-23 아스트라제네카 아베 피하 주사용 항-ifnar1 투여 요법
EP4337696A1 (en) 2021-05-12 2024-03-20 Astrazeneca AB Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
KR20240082399A (ko) 2021-10-04 2024-06-10 아스트라제네카 아베 루푸스의 치료
WO2024046305A1 (zh) 2022-08-29 2024-03-07 江苏恒瑞医药股份有限公司 免疫调节剂的筛选和制备方法
AU2023335543A1 (en) 2022-08-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fusion protein comprising taci polypeptide and use thereof
JP2025533978A (ja) * 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
WO2024241156A1 (en) 2023-05-19 2024-11-28 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
DE69214656T2 (de) 1991-08-30 1997-03-13 Genentech Inc Therapeutisches verfahren zur behandlung von iddm
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
JP3887011B2 (ja) 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
CA2171955A1 (en) 1993-09-17 1995-03-23 Michael G. Tovey Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU1289595A (en) 1993-11-15 1995-06-06 Cell Therapeutics, Inc. Method for selectively inhibiting il-2 signal transduction
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
EP1051626B1 (en) 1998-01-30 2009-03-18 Allertein Therapeutics, LLC Prognostic allergy or inflammation test
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
IT1321086B1 (it) 2000-11-24 2003-12-30 Cselt Centro Studi Lab Telecom Sistema e metodo per individuare la posizione di apparecchiaturemobili
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
MXPA03006100A (es) 2001-01-09 2005-02-14 Baylor Reserch Inst Metodos para tratar enfermedades auto inmunes en un sujeto y examenes de diagnostico en tubo de ensayo.
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004090390A1 (ja) 2003-04-02 2004-10-21 Kabushiki Kaisha Riken シールリング
MXPA05011409A (es) 2003-04-23 2005-12-12 Medarex Inc Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal.
CN1795010A (zh) 2003-04-23 2006-06-28 梅达雷克斯公司 针对α干扰素受体－1(IFNAR－1)的人源化抗体
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
PT1781705E (pt) * 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
CN101952454B (zh) * 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
KR20250092298A (ko) * 2021-04-23 2025-06-23 아스트라제네카 아베 피하 주사용 항-ifnar1 투여 요법

Also Published As

Publication number Publication date
US20160376370A1 (en) 2016-12-29
MX2007000023A (es) 2007-03-07
US20060029601A1 (en) 2006-02-09
LT2662390T (lt) 2017-10-10
US20200031945A1 (en) 2020-01-30
AU2005258077C1 (en) 2012-10-25
US10385133B2 (en) 2019-08-20
ES2643237T3 (es) 2017-11-21
KR20130012258A (ko) 2013-02-01
US9453077B2 (en) 2016-09-27
US20100143369A1 (en) 2010-06-10
CA2570823C (en) 2015-02-24
PL2662390T3 (pl) 2017-12-29
US11072664B2 (en) 2021-07-27
AU2005258077B2 (en) 2011-08-18
AU2005258077A1 (en) 2006-01-05
HK1105420A1 (en) 2008-02-15
KR20140033210A (ko) 2014-03-17
JP2015172088A (ja) 2015-10-01
JP2013006873A (ja) 2013-01-10
KR20070047286A (ko) 2007-05-04
SI2662390T1 (sl) 2017-10-30
WO2006002177A2 (en) 2006-01-05
RU2412202C2 (ru) 2011-02-20
CN102863532A (zh) 2013-01-09
DK1781705T3 (en) 2015-01-12
HUE035082T2 (en) 2018-05-02
CN101001878B (zh) 2012-09-26
SI1781705T1 (sl) 2015-01-30
PL1781705T3 (pl) 2015-03-31
US7662381B2 (en) 2010-02-16
KR101541658B1 (ko) 2015-08-07
US20130230534A1 (en) 2013-09-05
WO2006002177A3 (en) 2006-06-22
CN102603894B (zh) 2015-09-30
JP2008508864A (ja) 2008-03-27
EP1781705B1 (en) 2014-10-08
JP5160887B2 (ja) 2013-03-13
RU2010138567A (ru) 2012-03-27
ES2526194T3 (es) 2015-01-08
EP1781705A4 (en) 2008-11-26
KR101335079B1 (ko) 2013-12-12
CY1115875T1 (el) 2017-01-25
KR20150041193A (ko) 2015-04-15
EP1781705A2 (en) 2007-05-09
JP5899540B2 (ja) 2016-04-06
US8460668B2 (en) 2013-06-11
EP2662390B1 (en) 2017-08-02
PT1781705E (pt) 2014-12-23
CN101001878A (zh) 2007-07-18
CY1119512T1 (el) 2018-03-07
PT2662390T (pt) 2017-10-09
US20210395375A1 (en) 2021-12-23
RU2600884C2 (ru) 2016-10-27
CN102603894A (zh) 2012-07-25
CA2570823A1 (en) 2006-01-05
EP2662390A1 (en) 2013-11-13
RU2007102079A (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
DK2662390T3 (da) Interferon alpha receptor 1-antistoffer og anvendelse heraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
IL225633B (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IS8190A (is) Ný P2X7 viðtakamótlyf og notkun þeirra
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1673460T3 (da) Rekombinante vacciner og anvendelse af disse
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
NO20055731D0 (no) Cannabinoide reseptorligander og deres anvendelse
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
DK1957539T3 (da) Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
DK1513873T3 (da) Terapeutiske epitoper og anvendelser deraf
EP1827289A4 (en) IMPLANT AND IMPLANT ELEMENT
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
ATE435872T1 (de) Anti-interleukin-1 rezeptor antikörper und deren verwendung
DK1463759T3 (da) Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
DK1808446T3 (da) IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SM200300009B (it) Composizione e suo uso terapeutico
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
NO20044106L (no) Omkonstruerte baculoviruser og anvendelse derav
IS8404A (is) Nogo-A binding með aukinni sækni og lyfjafræðilegnotkun hennar